Therapeutic drug monitoring of anti‐tumour necrosis factor‐α agents in inflammatory bowel disease: Limits and improvements

Review of 7 publications found no major changes in TDM strategies, but a growing trend towards use of proactive TDM as it has shown it leads to a longer duration of response, lower rates of discontinuation & relapses. However, the available evidence is limited and of low quality

Source:

British Journal of Clinical Pharmacology